Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vyndaqel Capsules Special Investigation (ATTR-CM)
Sponsor: Pfizer
Summary
Secondary Data Collection : To confirm the safety and effectiveness profiles under the actual medical practice of Vyndaqel in Japan. This study is conducted in accordance with the protocol even when Vynmac is used, and information the use of Vynmac during the observation period is also collected.
Official title: Vyndaqel Capsules Special Investigation - Investigation on Patients With Transthyretin Amyloid Cardiomyopathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1214
Start Date
2019-10-03
Completion Date
2025-03-27
Last Updated
2026-05-18
Healthy Volunteers
No
Interventions
Treatment for TTR amyloidosis
The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
Treatment for TTR amyloidosis
The usual adult dose is 61 mg of tafamidis orally once daily.
Locations (1)
Pfizer
Tokyo, Japan